- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
The post Novel CD45-targeted TCR-T cell therapies designed to eliminate residual disease and prevent relapse following hematopoietic cell transplantation appeared first on TScan Therapeutics, Inc..
The post TSC-101 Eliminates Recipient Hematopoietic Cells and Demonstrates Potential for Improved Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning: Updated Results from the Phase 1 (ALLOHA) Trial appeared first on TScan Therapeutics, Inc..
The post TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial. appeared first on TScan Therapeutics, Inc..